Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney DiseaseDick de Zeeuw, Glenn M. Chertow, Tadao Akizawa et al.|New England Journal of Medicine|2013Cited by 990
Addition of Angiotensin Receptor Blockade or Mineralocorticoid Antagonism to Maximal Angiotensin-Converting Enzyme Inhibition in Diabetic NephropathyUzma F. Mehdi, Robert D. Toto, Beverley Adams‐Huet et al.|Journal of the American Society of Nephrology|2009Cited by 386
The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristicsDavid C. Wheeler, Hiddo J.L. Heerspink, Bergur V. Stefánsson et al.|Nephrology Dialysis Transplantation|2020Cited by 189
Rationale and design of the Kidney Precision Medicine ProjectIan H. de Boer, Jonathan Himmelfarb, Nir Hacohen et al.|Kidney International|2021Cited by 187
Long-term control of plasma calcitriol concentration in dogs and humans. Dominant role of plasma calcium concentration in experimental hyperparathyroidism.Henry N. Hulter, John C. Peterson, Bernard P. Halloran et al.|Journal of Clinical Investigation|1985Cited by 64